MSL
SRPT icon

Mackay Shields LLC’s Sarepta Therapeutics SRPT Stock Holding History

Mackay Shields LLC’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-22,009
Closed -$2.4M – 1438
2018
Q4 		$2.4M Buy
+22,009
New +$2.75M 0.02% 630
2018
Q3 		– Sell
-18,794
Closed -$2.48M – 1222
2018
Q2 		$2.48M Sell
18,794
-2,100
-10% -$198K 0.02% 700
2018
Q1 		$1.55M Buy
+20,894
New +$1.39M 0.01% 865

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Mackay Shields LLC's SRPT Position: Q1 2019 in Review

Mackay Shields LLC sold out of Sarepta Therapeutics (SRPT) in Q1 2019, closing a stake of 22,009 shares — an estimated $2.4M sold.

Mackay Shields LLC first reported a position in SRPT in Q1 2018 and held it in 3 quarters. The position peaked at $2.48M in Q2 2018. 371 funds tracked by Wall St. Rank hold SRPT as of Q1 2019.

  • Mackay Shields LLC reported no remaining Sarepta Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Mackay Shields LLC sold 22,009 Sarepta Therapeutics shares in Q1 2019, an estimated $2.4M.
  • Mackay Shields LLC first reported a position in Sarepta Therapeutics in Q1 2018 and held it in 3 quarters.
  • Mackay Shields LLC's Sarepta Therapeutics position peaked at $2.48M in Q2 2018.
  • 371 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2019.

Based on Mackay Shields LLC's 13F filing for Q1 2019, filed 13 May 2019.